A.R.T. Advisors’s Clearside Biomedical CLSD Stock Holding History

A.R.T. Advisors’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-6,549	Closed	-$95K	–	1467
2019 Q2	$95K	Buy	+6,549	New	+$117K	0.01%	1201
2019 Q1	–	Sell	-4,291	Closed	-$69K	–	1350
2018 Q4	$69K	Buy	+4,291	New	+$201K	﹤0.01%	1193
2017 Q1	–	Sell	-760	Closed	-$101K	–	1455
2016 Q4	$101K	Buy	+760	New	+$191K	0.01%	1148

Other funds holding CLSD

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SignatureFD Atlanta, Georgia $6.53B AUM 20.48% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

A.R.T. Advisors's CLSD Position: Q3 2019 in Review

A.R.T. Advisors sold out of Clearside Biomedical (CLSD) in Q3 2019, closing a stake of 6,549 shares — an estimated $95K sold.

A.R.T. Advisors first reported a position in CLSD in Q4 2016 and held it in 3 quarters. The position peaked at $101K in Q4 2016. 34 funds tracked by Wall St. Rank hold CLSD as of Q3 2019.

A.R.T. Advisors reported no remaining Clearside Biomedical position as of Q3 2019 after selling out during the quarter.
A.R.T. Advisors sold 6,549 Clearside Biomedical shares in Q3 2019, an estimated $95K.
A.R.T. Advisors first reported a position in Clearside Biomedical in Q4 2016 and held it in 3 quarters.
A.R.T. Advisors's Clearside Biomedical position peaked at $101K in Q4 2016.
34 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2019.

Based on A.R.T. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.